MindRank to Showcase AI-Driven Drug Discovery Platforms at ChinaBio® Partnering Forum 2024
MindRank
AI Drug Developer
ChinaBio®Cooperation Forum
2024.9.10-9.11
September 10-11, 2024, the 16th ChinaBio®The cooperation forum will be held in"Shanghai Pudong Kerry Hotel"Held. ChinaBio®Is a leading life sciences collaboration conference in China, dedicated to promoting cross-border cooperation in China's life sciences industry.
"MindRank"Invited to attend this conference and will"September 10th, 14:45-15:00"Delivered a keynote speech, sharing the clinical progress of the company's orally administered small-molecule GLP-1 receptor agonist MDR-001 and the development of its oncology drug pipeline, driven by its self-developed AI pharmaceutical platform.
At the same time,"MindRank"Will Unveil Latest AI Pharmaceutical Platform Product"Booth 1103", introducing the innovative application of the company's self-developed AI technology in the fields of small molecule, large molecule, and molecular glue drug research and development. We sincerely invite all colleagues to visit our booth for exchange.
For more information, please visit:
https://informaconnect.com/chinabio-partnering/agenda/2/
You can inPartneringONE®Cooperation system or via email bd@mindrank.aiContact us, looking forward to meeting you at ChinaBio®Expand new collaborations and partnerships.
About ChinaBio®
ChinaBio®The Collaboration Forum, co-initiated by ChinaBio Group and the U.S.-based EBD Group in 2009, has been held annually ever since and stands as the largest and most productive international collaborative conference in China’s life science sector. This year's forum will bring together 400+ companies and 800+ global decision-makers, executives, investors, and industry experts from the life sciences sector, featuring 1500+ one-on-one meetings to provide opportunities for the global biopharmaceutical community to establish partnerships within China’s life science market.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company’s vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.
MindRank's AI pharmaceutical solutions were rated by the authoritative European and American institution Deep Pharma Intelligence as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020." In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 start-up companies from mainland China making the list.
Related Reading:
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Cooperation: bd@mindrank.ai